- Barrons.com•2 days ago
After a few tough years, prospects for Trinity Biotech are finally looking up. In July, Trinity (TRIB), a maker of medical instruments and tests for diseases like HIV and diabetes, reported a return to revenue growth for the first time in over a year. Perhaps more notably, its Meritas Troponin point-of-care test, used to detect the presence of heart attacks in emergency room patients, and long the focus of investor attention, appears to be inching closer to Food and Drug Administration approval.
- Capital Cube•last month
Trinity Biotech Plc relative valuation is UNDERVALUED and it has a fundamental analysis score of 59.Our analysis is based on comparing Trinity Biotech Plc with the following peers – OraSure Technologies, Inc., Bio-Rad Laboratories, Inc. Class A, Alere Inc., Quidel Corporation, Chembio Diagnostics, Inc., Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc. and Vermillion, Inc. […] (Read more...) The post Trinity Biotech Plc: Strong price momentum but will it sustain? appeared first on CapitalCube.
Trinity Biotech plc (TRIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||8.12 x 100|
|Ask||13.25 x 500|
|Day's Range||12.79 - 13.15|
|52wk Range||9.20 - 16.40|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||55.45|
|Avg Vol (3m)||52,628|
|Dividend & Yield||0.00 (0.00%)|